CellXica Limited – Trademark Portfolio

Entity Type: 99

CellXica Limited holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 7 filings in this category. Currently, 7 trademarks are registered. Notable registered marks include M3Q, M5Q, GILTE, SDRFE, and EXSITE.

Building 7200,

Suite 7224 Cambridge Research Park, Beach Drive, Waterbeach Cambridge, Cambridgeshire CB25 9TL

7 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

CELLXICA
CELLXICA
Registered 2023
SDRFE
SDRFE
Registered 2023
M3Q
M3Q
Registered 2023
M5Q
M5Q
Registered 2023
GILTE
GILTE
Registered 2023
EXSITE
EXSITE
Registered 2023
CELLXICA
CELLXICA
Registered 2023

Trademark Classifications

CellXica Limited's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

9
Computers & Electronics (7 filings)

Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments

Frequently Asked Questions

How many trademarks does CellXica Limited have?

CellXica Limited has 7 U.S. trademarks filed with the USPTO. Of these, 7 registered.

What trademark classes does CellXica Limited file in?

CellXica Limited files trademarks across 1 Nice Classification class. The most active classes are Class 9 (Computers & Electronics). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.

What are CellXica Limited's most well-known trademarks?

CellXica Limited's registered trademark portfolio includes well-known marks such as M3Q, M5Q, GILTE, SDRFE, and EXSITE. These are among 7 currently registered trademarks in the portfolio.

What is CellXica Limited's trademark registration success rate?

CellXica Limited has a 100% trademark registration rate, with 7 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.